American College of Clinical Pharmacy
      Search      Cart
         
  Poster Hall

Sat-2 - Assessment of Unintentional Discontinuation of Guideline-Directed Medical Therapy for Heart Failure Following Intensive Care Unit Admission

Scientific Poster Session I - Students Research-in-Progress

Students Research in Progress
  Saturday, October 12, 2024
  11:30 AM–01:00 PM

Abstract

Introduction: Patients discharged from intensive care units (ICU) are at risk of unintentional discontinuation of medications for chronic conditions. This study aims to assess the rate of unintentional discontinuation of Guideline-Directed Medical Therapy (GDMT) for heart failure (HF) following ICU admission, identify associated risk factors, and understand the likelihood of restarting or discontinuing different GDMT categories.

Research Question or Hypothesis: What is the rate of unintentional discontinuation of GDMT for heart failure following ICU admission, and what are the associated risk factors?

Study Design: This single-center retrospective cohort study will use electronic health records from the adult medical critical care unit at The University of Oklahoma (OU) Health OU Medical Center (OUMC).

Methods: The study is descriptive, focusing on patients admitted to the ICU with HF from December 3, 2023, to May 3, 2024. Endpoints include: (1) incidence of GDMT for HF being temporarily held during ICU stay, (2) GDMT use following transitions of care, (3) factors associated with GDMT not being restarted after ICU transition, and (4) trends in discontinuation and reinitiation of medication classes used in GDMT for HF.

Descriptive statistics will characterize the study population. Categorical variables will be analyzed using Pearson ?2 tests or Chi-square tests; continuous variables will be analyzed using Student's t-tests or Wilcoxon rank-sum tests. Variables with a P value of less than 0.05 will be included in a multivariable log-binomial regression, with results reported as risk ratios (RRs).

Results: In progress

Conclusion: In progress

Presenting Author

Kayla Akin PharmD Candidate
University of Oklahoma Health Science Center College of Pharmacy

Authors

Jordan Fuller PharmD, MBA
University of Oklahoma College of Pharmacy